Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | CDC25B | P30305 | 1/20 | 0.63 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.53 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.53 |
| ▸ | MAOA | P21397 | 4/20 | 0.52 |
| ▸ | CES1 | P23141 | 3/20 | 0.52 |
| ▸ | APAF1 | O14727 | 2/20 | 0.52 |
| ▸ | TDP2 | O95551 | 2/20 | 0.52 |
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | S100A4 | P26447 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | TERT | O14746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anthraquinone SCHEMBL28961658 | 0.83 | CDC25B (0.80) | MEN1KMT2ACDC25BMAOACES1 | |
| Anthraquinone SCHEMBL4354119 | 0.83 | MEN1 (0.92) | MEN1KMT2ACDC25BMAOACES1 | |
| Anthraquinone SCHEMBL11352939 | 0.82 | MEN1 (0.60) | MEN1KMT2ACDC25BMAOACES1 | |
| Phentydrone SCHEMBL875187 | 0.80 | MEN1 (0.57) | MEN1KMT2ACDC25BMAOACES1 | |
| Anthraquinone SCHEMBL1901249 | 0.80 | MEN1 (1.00) | MEN1KMT2ACDC25BMAOACES1 | |
| Anthraquinone SCHEMBL14943 | 0.80 | MEN1 (1.00) | MEN1KMT2ACDC25BMAOACES1 | |
| Anthraquinone SCHEMBL29358690 | 0.80 | MEN1 (1.00) | MEN1KMT2ACDC25BMAOACES1 | |
| SCHEMBL545308 | 0.79 | MEN1 (0.55) | MEN1KMT2ACDC25BMAOACES1 | |
| SCHEMBL29519720 | 0.79 | MEN1 (0.55) | MEN1KMT2ACDC25BMAOACES1 | |
| SCHEMBL30950751 | 0.78 | MEN1 (0.55) | MEN1KMT2ACDC25BMAOACES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112204009-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-112204012-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-112204006-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-11-28 | — | — | CN | disclosed |
| CN-112154142-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-116348455-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-116283647-A | Prodrug modulators that integrate stress pathways | 卡里科生命科学有限责任公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115836056-A | NOTCH inhibitors and uses thereof | STEMSYNERGY疗法有限责任公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-113423685-B | Prodrug modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2022-11-29 | — | — | CN | disclosed |
| CN-113423685-A | Prodrug modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-09-21 | — | — | CN | disclosed |
| CN-112955438-A | Protein tyrosine phosphatase inhibitors and methods of use thereof | 卡里科生命科学有限责任公司 | 2021-06-11 | — | — | CN | disclosed |
| CN-112189008-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-05 | — | — | CN | disclosed |
| CN-112166113-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-01 | — | — | CN | disclosed |
| CN-112154142-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2020-12-29 | — | — | CN | disclosed |
| CN-111971071-A | CTLA-4-targeting DNA monoclonal antibodies for the treatment and prevention of cancer | 威斯塔解剖学和生物学研究所 | 2020-11-20 | — | — | CN | disclosed |
| CN-102382113-B | Comprise the solid form of the compound being used for the treatment of disease or disorder, its composition, and uses thereof | SIGNAL PHARM LLC (US) | 2016-04-06 | — | — | CN | disclosed |
| CN-104744475-A | mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/P13K/AKT pathway | SIGNAL PHARM LLC | 2015-07-01 | — | — | CN | disclosed |
| CN-104725384-A | Mtor Kinase Inhibitors For Oncology Indications And Diseases Associated With The Mtor/p13k/akt Pathway | SIGNAL PHARM LLC | 2015-06-24 | — | — | CN | disclosed |
| CN-102382113-A | Solid forms comprising 4-[9-(tetrahydro-furan-3-yl)-8-(2,4,6-trifluoro-phenylamino)-9h-purin-2-ylamino]-cyclohexan-1-ol, compositions thereof, and uses therewith | SIGNAL PHARM LLC | 2012-03-21 | — | — | CN | disclosed |
| CN-102245611-A | mTOR kinase inhibitors for use in mTOR/PI 3K/AKT/pathway-related oncology indications and diseases | SIGNAL PHARM LLC | 2011-11-16 | — | — | CN | disclosed |
| CN-101568544-A | Solid forms comprising 4- [ 9- (tetrahydro-furan-3-yl) -8- (2,4, 6-trifluoro-phenylamino) -9H-purin-2-ylamino ] -cyclohexan-1-ol, compositions thereof, and uses thereof | SIGNAL PHARM LLC (US) | 2009-10-28 | — | — | CN | disclosed |